Inowanzo Bvunzwa Mibvunzo Nezve Sunitinib Malate 丨 AASraw
MUTSVENE unoburitsa Cannabidiol (CBD) upfu uye Hemp Yakakosha Oiri muhuwandu!

Sunitinib Malate

 

  1. Sunitinib Malate Ongororo
  2. Chii Chatinoshandisa Sunitinib Malate Ye?
  3. Sei Sunitinib Malate Inoshanda?
  4. Sei Kutora Sunitinib Malate?
  5. Sei Kuchengeta Sunitinib Malate?
  6. Zvakawanda Sei Isu Tinoziva Zveshuwa Migumisiro YeSunitinib Malate?
  7. Ndezvipi Zvimwe Zvinodhakwa Zvinokanganisa Sunitinib Malate?
  8. FDA inobvumira Sunitinib Malate SeAdjuvant Kurapa KweRenal Cell Carcinoma
  9. Ndekupi Kwandinogona Kutenga Sunitinib Malate Pamhepo?

 

Sunitinib Malate (CAS:341031-54-7) yakawanikwa kuSUGEN, kambani yebiotechnology iyo yaipayona protein kinase inhibitors. Yaive yechitatu mune akateedzana emakomputa anosanganisira SU5416 uye SU6668. Pfungwa iyi yaive yeATP mimic iyo yaigona kukwikwidzana neATP yekusunga kune inoitisa saiti yeanogamuchira tyrosine kinases. Pfungwa iyi yakatungamira mukugadzirwa kweakawanda madiki-mamorekuru tyrosine kinase inhibitors, kusanganisira Gleevec, Sutent, Tarceva nevamwe vazhinji.

 

Sunitinib Malate Ongororo

Sunitinib Malate yero kuita orenji poda. Sunitinib Malate idiki-mamorekuru akawanda akanangwa receptor tyrosine kinase (RTK) inhibitor. Musi waNdira 26, 2006, mumiririri akagamuchirwa nenzira yakasarudzika neUS FDA yezviratidzo zvekurapa renal cell carcinoma (RCC) uye imatinib-inodzivirira gastrointestinal stromal tumor (GIST). Nezvinangwa izvi, Sunitinib Malate inowanzo kuwanikwa seyakagadziriswa nemuromo. Sunitinib Malate inhibisa maseru ekuratidzira nekutarisa maRTK mazhinji. Izvi zvinosanganisira zvese platelet-inotorwa yekukura factor receptors (PDGF-R) uye vascular endothelial grow factor receptors (VEGF-R). Sunitinib Malate zvakare inhibits KIT (CD117), iyo RTK inotyaira ruzhinji rweGIST. Uye zvakare, Sunitinib Malate inhibits mamwe maRTK anosanganisira RET, CSF-1R, uye flt3.

 

Chii Chatinoshandisa Sunitinib Malate Ye? 

Sunitinib Malate inoshandiswa kurapa vanhu vakuru vane kenza yeitsvo isina kupararira (localized) uye vari panjodzi huru yeRCC yekudzoka zvakare mushure mekuvhiyiwa itsvo.

Sunitinib Malate inoshandiswa kurapa kenza yepamusoro yeitsvo (advanced renal cell carcinoma kana RCC).

Sunitinib Malate inoshandiswa kurapa kenza isingawanzoitika yemudumbu, ura, kana hosha inonzi gastrointestinal stromal bundu (GIST) uye kana iwe watora mushonga imatinib mesylate uye haina kumisa kenza kukura kana iwe haugone kutora imatinib mesylate. Gleevec chiratidzo chakanyoreswa cheNovartis Pharmaceuticals Corporation.

Sunitinib Malate inoshandiswa kurapa mhando yekenza yepancreatic inozivikanwa sepancreatic neuroendocrine tumors (pNET) yakafambira mberi uye isingakwanise kurapwa nekuvhiyiwa.

 

Sei Sunitinib Malate Inoshanda?

Sunitinib Malate idiki-mamorekuru inhibitor yeakawanda receptor tyrosine kinases, mamwe acho anokosheswa mukukura kwemota, pathologic angiogenesis, uye metastatic kufambira mberi kwekenza. Mumiririri unodzivisa platelet-yakatorwa kukura chinhu receptors - (PDGFRcy uye PDGFRβ), vascular endothelial grow factor receptors (VEGFR1, VEGFR2, uye VEGFR3), stem cell factor receptor (KIT), FMS-senge tyrosine kinase 3, koloni-inosimudzira factor receptor mhando 1, uye iyo glial cell-mutsara yakatorwa neurotrophic factor receptor (RET). Sunitinib Malate inhibition yechiitiko uye mashandiro eaya receptor tyrosine kinases yakaratidzirwa mune biochemical uye cellular assays uye cell kuwanda assays. Iyo yekutanga metabolite yeSunitinib Malate inoratidza potency yakafanana neiyo mubereki mubatanidzwa mune biochemical uye cellular assays.

Sunitinib Malate inhibits phosphorylation yeakawanda receptor tyrosine kinases (PDGFRβ, VEGFR2, KIT) mune bundu xenograf inoratidzira receptor tyrosine kinase zvinangwa mu vivo uye inhibits bundu kukura uye metastasis mune mamwe maitiro ekuyedza. Mumiririri unodzivirira kukura kwemamota maseru anoratidza kudzvanywa kwakanangana nekero receptor tyrosine kinases (PDGFR, RET, kana KIT) mu vitro uye PDGFRβ-uye VEGFR2-inoenderana nethumba angiogenesis mu vivo.

 

Sunitinib Malate

 

Sei Kutora Sunitinib Malate?

Iyo Sunitinib Malate muyero unorayirwa nachiremba wako zvinoenderana nezvinhu zvinoverengeka. Izvi zvinosanganisira:

❶ mhando uye kuomarara kwechimiro chauri kushandisa Sunitinib Malate kurapa

❷ mamwe marapirwo aungave uine

❸ mimwe mishonga yauri kutora

Chiremba wako anozopedzisira agadza dosi diki iyo inopa zvaunoda.

Ruzivo runotevera runotsanangura madosi ayo anowanzo shandiswa kana kukurudzirwa. Zvisinei, iva nechokwadi chekutora muyero uyo chiremba wako anokuraira iwe. Chiremba wako achasarudza yakanakisa dosi kuti ikwane zvaunoda.

 

Forms Mafomu emishonga uye simba

Sunitinib Malate inouya sekapuleti yaunomedza. Inowanikwa mune aya masimba: 12.5 milligrams (mg), 25 mg, 37.5 mg, uye 50 mg.

 

♦ Chiyero chegomarara repamuviri

Iyo yakajairwa muyero weSunitinib Malate yematumbo stromal tumors (GISTs) ndeye 50 mg kamwe pazuva pazuva kwevhiki ina. Izvi zvinoteverwa nevhiki mbiri pasina mushonga. Ipapo, iwe unodzokorora iyo kutenderera.

Iwe ungangoenderera nekutora Sunitinib Malate kudzamara kenza yako yawedzera kana muviri wako usingakwanise kutsungirira kurapwa nemushonga. Chiremba wako anoona kana iwe uchifanira kurega kutora Sunitinib Malate. Kuti uwane ruzivo rwekuti Sunitinib Malate inoshandiswa sei kurapa maGIST, ona chinongedzo sezasi.

 

♦ Chiyero chegomarara reitsvo

Sunitinib Malate inoshandiswawo kurapa mhando yekenza yeitsvo inonzi advanced renal cell carcinoma (RCC). Iyo yakajairwa muyero weSunitinib Malate yepamberi RCC ndeye 50 mg kamwe pazuva pazuva kwevhiki ina. Izvi zvinoteverwa nevhiki mbiri pasina mushonga. Ipapo, iwe unodzokorora iyo kutenderera.

Iwe ungangoenderera nekutora Sunitinib Malate kudzamara kenza yako yawedzera kana muviri wako usingakwanise kutsungirira kurapwa nemushonga. Chiremba wako anoona kana iwe uchifanira kurega kutora Sunitinib Malate. Kuti uwane rumwe ruzivo nezvekuti Sunitinib Malate inoshandiswa sei kurapa epamberi RCC, ona chinongedzo sezasi.

 

♦ Chiyero chekurapa kwekuwedzera kwekenza yeitsvo

Sunitinib Malate inoshandiswawo sechirevo chekurapa chemhando yekenza yeitsvo inonzi RCC mushure meiyo nephrectomy (iyo yekuvhiya kubviswa kweitsvo). Zvakajairika kuyerwa kwe Sunitinib Malate kwekushandisa uku kuri 50 mg kamwe pazuva pazuva kwemavhiki mana. Izvi zvinoteverwa nevhiki mbiri pasina mushonga. Iwe unowanzo dzokorora kutenderera uku kusvika kapfumbamwe. Kuti uwane ruzivo rwekuti Sunitinib Malate inoshandiswa sei seanobatsira kurapwa kweRCC, ona chinongedzo sezasi.

 

♦ Muyero wekenza yepancreatic

Iyo yakajairwa muyero weSunitinib Malate yepamberi pancreatic neuroendocrine tumors (pNETs) iri 37.5 mg kamwe pazuva.

Iwe ungangoenderera nekutora Sunitinib Malate kudzamara kenza yako yawedzera kana muviri wako usingakwanise kutsungirira kurapwa nemushonga. Chiremba wako anoona kana iwe uchifanira kurega kutora Sunitinib Malate.

 

Noted: chipimo chemushonga chaingova chirevo, ndokumbirawo ubatsire kutarisa rumwe ruzivo newebsite ino.www.dda.gov .

 

AASraw ndiye nyanzvi yekugadzira Sunitinib Malate.

Ndokumbirawo ubaye pano kuti uwane ruzivo Cont Cont us

 

Sei Kuchengeta Sunitinib Malate?

Chengetedza mishonga iyi mumudziyo iyo yakauya, yakasimba yakavharwa, uye kunze kwekusvika kwevana. Zvichengetedze pamusasa wekupisa uye kure nekupisa kwakanyanya uye unyoro (kwete muimba yekugezera).

Zvakakosha kuchengetedza mishonga yose isingaoneki uye kusvika kune vana semiti yakawanda (yakadai sepiritsi yevhiki nevhiki uye yeavo madonhe emeso, makemikari, makanda, uye inhalers) haisi vana vasingagoneki uye vana vaduku vanogona kuvhura nyore nyore. Kuchengetedza vana vaduku kubva muchetura, nguva dzose chengetedza kuchengetedzwa kwekuchengetedza uye pakarepo ita mishonga munzvimbo yakachengeteka - imwe yakasimuka uye kure uye isati yavaona uye inosvika.

Mishonga isingadiwe inofanirwa kuraswa nenzira dzakakosha kuona kuti zvipfuyo, vana, nevamwe vanhu havagone kuzvidya. Nekudaro, iwe haufanire kuburitsa uyu mushonga pasi pechimbuzi. Pane kudaro, nzira yakanakisa yekurasa yako mishonga ndeye kuburikidza neyekurapa-kudzosa chirongwa. Taura nachiremba wako kana kuti taura nedhipatimendi rako remarara / rekudzokorora kuti udzidze nezve zvirongwa zvekudzosa munharaunda yako. Ona iyo FDA's Safe Disposal ye Mishonga webhusaiti kuti uwane rumwe ruzivo kana iwe usina mukana wekutora kudzoka chirongwa.

 

Zvakawanda Sei Isu Tinoziva Zveshuwa Migumisiro YeSunitinib Malate?

Sunitinib Malate zviitiko zvakashata zvinoonekwa sezvisingakwanisike uye zviitiko zvezviitiko zvakakomba zvakashata zvakaderera.

Zviitiko zvakajairika zvakanyanya zvinosanganiswa neSunitinib Malate kurapa kuneta, manyoka, kusvotwa, kushaya anorexia, hypertension, yero ganda kutsvuka, ruoko-tsoka tsoka kuita, uye stomatitis. kazhinji neSunitinib Malate pane placebo yaisanganisira manyoka, anorexia, ganda kushanduka, mucositis / stomatitis, asthenia, yakachinja kuravira, uye kupatira. Kuderedzwa kwemadhiza kwaidikanwa mu50% yevarwere vakadzidza muRCC kuitira kuti vagadzirise huturu hwakakosha hwemumiriri uyu.

Zvakakomba (giredhi 3 kana 4) zviitiko zvakashata zvinoitika mu10% yevarwere uye zvinosanganisira hypertension, kuneta, asthenia, manyoka, uye chemotherapy-inosimudzira acral erythema. Lab kusanzwisisika kwakabatana neSunitinib Malate therapy inosanganisira lipase, amylase, neutrophils, lymphocytes, uye maplatelet. Hypothyroidism uye erythrocytosis inodzoserwa zvakare yakabatana neSunitinib Malate. Zviitiko zvizhinji zvakashata zvinogona kutarisirwa kuburikidza nekuchengetedzwa kwekutsigira, kukanganiswa kwedosi, kana kudzikisira dosi.

Ongororo ichangoburwa yakaitwa pa MD Anderson Cancer Center yakafananidza mhedzisiro ye metastatic renal cell cancer varwere vakagamuchira Sunitinib Malate pane yakajairwa purogiramu (50 mg / 4 mavhiki pa2 mavhiki abva) neavo vakagamuchira Sunitinib Malate neakawandisa uye mapfupi emahara emishonga (imwe purogiramu). Izvo zvakaonekwa kuti kupona kwese, kufambira mberi kwekusununguka kwemahara uye kutevedzera zvinodhaka zvaive zvakanyanya zvakanyanya muvarwere vakagamuchira Sunitinib Malate pane imwe purogiramu. Varwere zvakare vaive nekushivirira zvirinani uye kudzikisira kuomarara kwezviitiko zvakashata izvo zvinowanzo kutungamira mukuregera kurapwa kweanoshambadza renal cancer cancer varwere.

 

Sunitinib Malate

 

Ndezvipi Zvimwe Zvinodhakwa Zvinokanganisa Sunitinib Malate?

Sunitinib Malate inogona kukonzera dambudziko rakakomba remoyo. Ngozi yako inogona kuve yakakwira kana iwe ukashandisawo mimwe mishonga yekurapa hutachiona, asima, matambudziko emwoyo, kuwedzerwa kweropa, kushushikana, chirwere chepfungwa, gomarara, malaria, kana HIV.

Dzimwe nguva hazvina njodzi kushandisa mimwe mishonga panguva imwe chete. Mimwe mishonga inogona kukanganisa ropa rako remamwe madhiragi aunotora, ayo anogona kuwedzera mhedzisiro kana kuita kuti mishonga isanyanya kushanda. Udza chiremba wako nezve mimwe yako mishonga, kunyanya: osteoporosis mushonga.

Urongwa urwu hauna kukwana. Mimwe mishonga inogona kukanganisa Sunitinib Malate, kusanganisira mishonga yemishonga uye inopfuura-the-counter mishonga, mavitamini, uye mishonga yemiti. Hakusi kwese kusangana kwekushandisa zvinodhaka kwakanyorwa pano.

 

FDA inobvumira Sunitinib Malate SeAdjuvant Kurapa KweRenal Cell Carcinoma

Musi waNovember 16, 2017, Chikafu neDrug Administration chakabvumidza Sunitinib Malate (Sunitinib Malate, Pfizer Inc.) yekurapa kwekubatsira kwevarwere vakuru vari panjodzi huru yekudzokorora renal cell carcinoma inotevera nephrectomy.

Kubvumidzwa kwaive kwakavakirwa pane yakawanda-yepakati, yepasi rose, yakapofumara-yakapetwa, inochengetedzwa nenzvimbo, kutongwa (S-TRAC), mune varwere ve615 vane njodzi huru yekudzokorora RCC inotevera nephrectomy. Varwere vakasarudzika 1: 1 kuti vagamuchire kana 50 mg Sunitinib Malate kamwe zuva nezuva, mavhiki e4 pakurapwa kunoteverwa ne2 mavhiki kubva, kana placebo. Kurarama kweMedian-kusununguka kwevarwere vanotora Sunitinib Malate yaive makore 6.8 (95% CI: 5.8, isina kusvika) ichienzaniswa nemakore 5.6 (95% CI: 3.8, 6.6) yevarwere vanogamuchira placebo (HR = 0.76; 95% CI: 0.59 , 0.98; p = 0.03). Panguva yekuongorora kweDFS, data rekupona rese rakanga risati rakura.

Mhedzisiro inowanzoitika (≥25%) kune Sunitinib Malate kuneta / asthenia, manyoka, mucositis / stomatitis, kuda kurutsa, kushaya kudya / anorexia, kurutsa, kurwadziwa kwepamuviri, ruoko-tsoka tsoka, hypertension, kubuda ropa zviitiko, dysgeusia / shanduko yakachinja , Dyspepsia, uye thrombocytopenia. Iko kunyorera kune yambiro yebhokisi yekuzivisa vashandi vezvehutano nevarwere nezve njodzi yekuzvimba hepatoxicity, izvo zvinogona kukonzera kukundikana kwechiropa kana kufa.

Iyo yakakurudzirwa dhijitari yeSunitinib Malate yekurapa kwekuwedzera kweRCC ndeye 50 mg muromo kamwe kamwe pazuva, uine kana usina chikafu, 4 mavhiki pakurapwa uchiteverwa nemavhiki maviri ekuenda kune mapfumbamwe-masvondo evhiki.

 

Noted: Ruzivo ruzere runowanikwa pa:neworleans.fda.gov  PDF 

 

Ndekupi Kwandinogona Kutenga Sunitinib Malate Pamhepo? 

Kune vazhinji vatengesi / vagadziri veSunitinib Malate poda mumusika, kutsvaga chaiko kwakakosha kwazvo kuvanhu vese vanoda chigadzirwa ichi nekukurumidza. Kana isu tasarudza kutenga Sunitinib Malate powder mumusika, tinofanirwa kudzidza rumwe ruzivo nezvazvo, kuziva mashandisiro uye mashandiro ekuita, chero njodzi patinotora Sunitinib Malate powder…. Uye zvakare, mutengo uye mhando zvinofanirwa kuve zvatinonetsekana tisati tazvitenga.

Mushure mekunge taongorora dhata kubva kumusika, tichienzanisa vatengesi vazhinji, AASraw inotarisa sarudzo dzakanaka kune avo vanhu vanoda kutenga zvakawanda Sunitinib Malate upfu, kugadzirwa kwavo kwaidzorwa zvakanyanya pasi peCGMP mamiriro, hunhu hunogona kuteverwa chero nguva uye ivo vangangopa ese miedzo yekuyedza kana iwe ukairaira. Kana iri iyo Sunitinib Malate poda inodhura / mutengo, zvinofanirwa kuve zvine musoro, mumaziso angu. Nekuti ini ndawana mitengo yakawanda kubva kune akasiyana Sunitinib Malate vatengesi, zvichienzaniswa nehunhu, ndinofunga aasraw ichave isiri yakaipa sarudzo.

AASraw ndiye nyanzvi yekugadzira Sunitinib Malate.

Ndokumbirawo ubaye pano kuti uwane ruzivo Cont Cont us

 

Reference

[1] Kudya neDrug Administration. Sunitinib (Sutent) Kurondedzera ruzivo. 2015.

[2] CA Naranjo, U. Busto, uye EM Sellers, "Nzira yekufungidzira mikana yekusagadzikana kwezvinodhaka," Clinical Pharmacology uye Therapeutics, vol. 30, kwete. 2, mapeji 239–245, 1981.

[3] Z. Ansari naMK George, "Zvinodhaka-zvinokonzerwa nehutachiona-hunowirirana thrombocytopenia yechipiri kune sunitinib mune murwere ane metastatic renal cell carcinoma: nyaya yenyaya," Journal of Medical Case Reports, vol. 7, chinyorwa 54, 2013.

[4] K. Sakai, K. Komai, D. Yanase, uye M. Yamada, "Plasma VEGF sechiratidzo chekuongororwa uye kurapwa kwevasculitic neuropathy," Zvinyorwa zveNeurology, Neurosurgery uye Psychiatry, vol. 76, kwete. 2, chinyorwa 296, 2005.

[5] European Medicines Agency. Sunitinib (SUTENT). Pfupiso yeChigadzirwa Unhu. 2015.

[6] Pajares B, Torres E, Trigo JM et al. Tyrosine kinase inhibitors uye kusangana kwezvinodhaka: ongororo ine mazano anobatsira. Kliniki Dudziro Oncol 2012; 14: 94-101.

[7] Teo YL, Ho HK, Chan A. Metabolism-inoenderana pharmacokinetic mishonga-zvinodhaka kusangana ne tyrosine kinase inhibitors: ikozvino kunzwisisa, matambudziko uye kurudziro. Br J Clin Pharmacol 2015; 79: 241-253.

[8] Jamie Dlugosch (2009-03-13). "Ko biologics uye Sutent ichaponesa Pfizer?". InvestorPlace.

[9] BMJ 31-Jan-2009 "ZVAKANAKA uye kunetsekana kwemishonga yegomarara" p271

[10] Blay JY, Reichardt P (Chikumi 2009). "Yepamberi dumbu stromal bundu muEurope: wongororo yakagadziridzwa yekurapa kurudziro". Nyanzvi Rev Anticancer Ther. 9 (6): 831-8. doi: 10.1586 / era.09.34. PMID 19496720. S2CID 23601578.

0 zvaanofarira
1054 Views

Ungazvidyawo kufanana

Comments dzakavharika.